NCT06618313

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

Open-label, Single-arm，Exploratory Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Beijing GoBroad Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma

Detailed description

Patient will receive study treatment in the treatment observation period. After the end of the treatment observation period, patients will be allowed to continue to receive treatment if there is no major safety problems and the investigator judges that the patient may continue to benefit.

Conditions

• B-Cell Non-Hodgkin Lymphoma-Recurrent
• B-Cell Non-Hodgkin Lymphoma-Refractory

Interventions

Type	Name	Description
DRUG	JCXH-213,an mRNA-LNP based in vivo CAR therapy	JCXH-213 infusion

Timeline

• Start date: 2025-03-27
• Primary completion: 2026-08-01
• Completion: 2026-12-01
• First posted: 2024-10-01
• Last updated: 2025-06-03

Locations

1 site across 1 country: China